Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. Gefiltert nach profit streak "Full 10 yr", Has report: 26 match(Filter löschen).

# Titel Mkt Cap Score 10Y ROE Profit Streak Net Debt/Eq Gross Margin Analyse FY
1 NetEase Inc NTES · USA $85B
92/100 Exzellent
21.6%low 13.4% 10 yr+ Net cash 57% NetEase, Inc. Deep-Dive-Research15. Juni 2026 · Halten FY2025
2 Arista Networks ANET · USA $227B
88/100 Exzellent
24.1%low 15.3% 10 yr+ Net cash 64% Arista Networks: Eine Langfriststudie zum Marktführer im Data-Center-Switching23. Mai 2026 · Beobachten FY2025
3 Belimo Holding BEAN · SW $13B
88/100 Exzellent
22.5%low 17.7% 10 yr+ Net cash 44% Belimo Holding: Ein Premium-HVAC-Compounder mit eingepreister KI-Kühlungs-Perspektive27. Juni 2026 · Beobachten FY2025
4 Meta Platforms Inc. META · USA $1.4T
84/100 Exzellent
24.3%low 17.3% 10 yr+ 0.0× 82% Meta Platforms: Eine Studie über eine Deep-Value-Anlage19. Mai 2026 · Beobachten FY2025
5 GlaxoSmithKline PLC ADR GSK · USA $103B
84/100 Exzellent
34.6%low 18.4% 10 yr+ 0.9× 68% GSK plc: Neu aufgebaute Biopharma, im Wettlauf mit der Patentklippe27. Juni 2026 · Halten FY2025
6 Accton Technology Corp 2345 · Taiwan $45B
83/100 Exzellent
33.5%low 21.4% 10 yr+ Net cash 20% Accton Technology Tiefgehende Research-Analyse14. Juni 2026 · Halten FY2025
7 Taiwan Semiconductor Manufacturing TSM · USA $2.1T
82/100 Exzellent
26.3%low 21.8% 10 yr+ Net cash 53% TSMC: Eine tiefgehende Value-Investing-Studie22. Mai 2026 · Beobachten FY2025
8 Tencent Holdings Ltd 0700 · Hongkong $548B
82/100 Exzellent
21.1%low 13.2% 10 yr+ Net cash 48% Tencent Holdings: Eine tiefgehende Research-Studie28. Mai 2026 · Vorsichtiger Kauf FY2025
9 NVIDIA Corporation NVDA · USA $4.9T
81/100 Exzellent
39.9%low 19.8% 10 yr+ Net cash 64% NVIDIA Investment-Memo22. Mai 2026 · Beobachten FY2026
10 Sika AG SIKA · SW $37B
80/100 Exzellent
22.8%low 15.7% 10 yr+ 0.7× 45% Sika AG: Qualitäts-Compounder in einem zyklischen Luftloch27. Juni 2026 · Halten FY2025
11 Straumann Holding AG STMN · SW $20B
80/100 Exzellent
21.3%low 7.6% 10 yr+ 0.1× 74% Straumann Holding AG: Marktführer der Dentalplattform zu einem anspruchsvollen Preis27. Juni 2026 · Halten FY2025
12 Heico Corporation HEI · USA $50B
78/100 Stark
15.7%low 12.8% 10 yr+ 0.5× 41% HEICO Corporation: Eine tiefgehende Analyse15. Juni 2026 · Halten FY2025
13 Shenzhen Inovance Tech 300124 · Shenzhen $24B
76/100 Stark
18.2%low 11.0% 10 yr+ Net cash 37% Tiefgehende Analyse zu Inovance Technology15. Juni 2026 · Halten FY2025
14 Intertek Group PLC ITRK · LSE $11B
75/100 Stark
30.4%low 22.5% 10 yr+ 1.2× 32% Intertek: Qualitäts-Compounder im Übernahmeangebot17. Juni 2026 · Halten FY2025
15 SGS SA SGSN · SW $24B
74/100 Stark
48.5%low 30.6% 10 yr+ 3.3× 48% SGS: Hochwertiger TIC-Compounder zum vollen Wert17. Juni 2026 · Halten FY2025
16 Sungrow Power Supply Co Ltd 300274 · Shenzhen $30B
72/100 Stark
18.6%low 9.3% 10 yr+ Net cash 25% Sungrow Power Supply: Hochwertiges Wachstum in einer zyklischen Hülle27. Juni 2026 · Halten FY2025
17 Toll Brothers Inc TOL · USA $14B
71/100 Stark
15.1%low 9.0% 10 yr+ 0.2× 23% Toll Brothers Tiefgehende Aktienanalyse15. Juni 2026 · Halten FY2025
18 Bureau Veritas SA BVI · Paris $13B
70/100 Stark
27.2%low 10.1% 10 yr+ 1.0× 30% Bureau Veritas: Qualitäts-TIC, eingepreist auf Wiederbeschleunigung17. Juni 2026 · Halten FY2025
19 New York Times Company NYT · USA $12B
69/100 Stark
10.6%low 0.5% 10 yr+ Net cash 51% The New York Times: Bündelökonomik zum vollen Preis17. Juni 2026 · Halten FY2025
20 Shenzhen Envicool Technology Co Ltd 002837 · Shenzhen $8.3B
66/100 Stark
12.9%low 10.0% 10 yr+ Net cash 32% Envicool Tiefgehende Analyse14. Juni 2026 · Beobachten FY2025
21 AstraZeneca PLC AZN · USA $279B
64/100 Mittel
15.4%low 0.3% 10 yr+ 0.5× 78% AstraZeneca: Eine eingehende Analyse15. Juni 2026 · Halten FY2025
22 Contemporary Amperex Technology Co., Limite 3750 · Hongkong $380B
62/100 Mittel
16.7%low 8.7% 10 yr+ Net cash 29% CATL: Eine Tiefenanalyse im Zen Horizon Framework4. Juni 2026 · Vorsichtiger Kauf FY2025
23 Anji Microelectronics Tech Co Ltd 688019 · Shanghai $7.6B
57/100 Mittel
15.4%low 7.4% 10 yr+ Net cash 58% Anji Technology: Importsubstitution bei CMP-Materialien und die zweite Kurve14. Juni 2026 · Halten FY2025
24 Shandong Zhongji Electrical Equipment Co Ltd 300308 · Shenzhen $141B
51/100 Mittel
13.4%low 1.8% 10 yr+ Net cash 28% Innolight (Zhongji Innolight): Eine tiefgehende Value-Investment-Studie21. Mai 2026 · Beobachten FY2025
25 NAURA Technology Group Co Ltd 002371 · Shenzhen $70B
50/100 Mittel
9.4%low 2.9% 10 yr+ Net cash 39% NAURA Technology Group SUN-R Investmentanalyse16. Juni 2026 · Beobachten FY2025
26 WuXi XDC Cayman Inc 2268 · Hongkong $8.8B
48/100 Eher schwach
17.4%low 5.2% 10 yr+ Net cash 30% WuXi XDC: Skalierung des ADC-Fertigungsnetzwerks17. Juni 2026 · Halten FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.